Innovative digital imaging technology meets increasing number of biopsies
Lumito develops an innovative novel imaging technology. Using the company’s digital images, pathologists and researchers can obtain a more complete histological basis for analyses and clinical diagnostics.
We want to offer a powerful tool to meet the demands of rapid and safe tissue diagnostics. The plan is to launch our first product for research labs by the end of 2022, followed by a clinical product.
The scanner also takes pictures of traditional hematoxylin and eosin-stained tissue sections, as well as of chromogen-based immunohistochemistry (IHC).
Higher analysis quality and shorter analysis times
The technology makes it possible to obtain images with higher contrast, increased dynamic range and reduced non-specific background. By achieving higher analysis quality and shorter analysis times, there is potential to significantly improve the diagnostics of tissue samples.
It is also possible to switch between visualization of the morphology and our unique UCNP IHC marking. The flexibility of the system also allows visualization of both readings simultaneously, superimposed on the same image. Altogether, this provides more detailed information, without the problems of overlapping and non-specific marking obtained with traditional methodology.
Lumito has recently completed a pre-study together with Umeå University, led by Associate Professor Daniel Öhlund, with good results. The research team has identified how the company’s UCNP technology can be used to improve the ability to visualize protein expression in pancreatic cancer.
Using Lumito’s imaging technology, we have investigated, among other things, whether a certain protein spreads via secretion from the cancer cells to the tumor’s supporting tissue, the tumor stroma. Lumito’s technology has led to greater possibilities, compared to other immunohistochemical methods, to visualize the penetration of secreted proteins in the tumor stroma, says Daniel Öhlund.
The images show the nucleus and HER2 respectively, in exactly the same cells and the same tissue section.
Contact with research teams
We have several ongoing studies, and are interested in approaching more research teams for collaboration to identify where our product can have the greatest impact. If you are interested in discussing a prospective collaboration and would like to know more about our technology, please contact our Product Specialist Tim Nilsson, e-mail: firstname.lastname@example.org, ph: +46 72 572 10 90 for further information.